CHOP researchers have defined a 3-tiered molecular classification of pediatric differentiated thyroid cancer, where fusion oncogenes predict the most invasive behavior.

Diva De León-Crutchlow, MD, MSCE, assumed the role of Director of the Congenital Hyperinsulinism Center in 2013 and was named Chief of the Division of Endocrinology and Diabetes in 2018.

Parents are usually blindsided when they find out that their child has congenital hyperinsulinism (HI), a rare genetic disorder that depresses blood sugar to dangerously low levels.

Low blood sugar is one of the symptoms of Kabuki syndrome, a genetic disorder that affects multiple systems in the body but can be tricky to diagnose.

A pilot study at CHOP is the first to demonstrate the effectiveness of the bihormonal bionic pancreas in hyperinsulinism patients.

The landmark TODAY2 study found that those diagnosed with type 2 diabetes during childhood and adolescence have a high risk of developing serious health complications by early adulthood.

In a special segment broadcast in Panama in September, Diva D. De León-Crutchlow, MD, MSCE, recalled her path from her home county to her role as Chief of the Division of Endocrinology and Diabetes and Director of the Congenital Hyperinsulinism Center at Children's Hospital of Philadelphia (CHOP).

Prediabetes is a serious condition that can be managed or reversed by making healthy diet and lifestyle choices.

Previous research has linked exposure to bisphenol A (BPA) in the womb with higher rates of obesity and diabetes later in life, but the biological mechanisms driving those changes have largely remained a mystery.

A unique CHOP clinic treats kids with radioactive iodine-refractory thyroid cancer.